In 2005, the FDA approved Singulair for the relief of symptoms of perennial allergic rhinitis, or indoor allergies, in adults and children six months of age and older. Available as a convenient once-a-day tablet, Singulair has been proven to help relieve a broad range of indoor and outdoor allergy symptoms for up to 24 hours.
Singulair regularly leads its class in sales in the United States and internationally. Singulair continues to show healthy growth as more and more physicians and patients turn to Singulair to help treat asthma and symptoms of allergic rhinitis. A recent clinical study found that children using Singulair maintained similar growth rates compared with children taking placebo.
To support the ongoing strong performance of Merck products, Merck scientists continue to seek new indications that will help bring relief to additional patients. Research on additional indications for Singulair is in late-stage development.
Allergies and asthma shouldn't interfere with the everyday fun of being a kid. Singulair now provides a different way to treat both indoor and outdoor allergies.
